From Concept To Reality: Fujifilm Forges A Path To Future Growth With SUT
By Stewart McNaull, Ph.D., Fujifilm Diosynth
In 2009, Fujifilm Diosynth Biotechnologies (Fujifilm), a biologics CDMO for over 20 years, sought to expand its cell culture operations to meet the industry’s need for more manufacturing capacity. Fujifilm began to look at single-use technology (SUT), and questioned if it offered the same performance as stainless steel when it came to cell growth, cellular productivity, and product quality? By learning the answer to this question and others about SUT, Fujifilm was able to use its knowledge as early adopters, expand its business capabilities, and, as a result, look forward to new growth well into the future.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.